Identification and characterization of novel TRPM1 autoantibodies from serum of patients with melanoma-associated retinopathy

Juliette Varin, Margaret M. Reynolds, Nassima Bouzidi, Sarah Tick, Juliette Wohlschlegel, Ondine Becquart, Christelle Michiels, Olivier Dereure, Robert M. Duvoisin, Catherine W. Morgans, José Alain Sahe, Quentin Samaran, Bernard Guillot, José S. Pulido, Isabelle Audo, Christina Zeitz

Research output: Contribution to journalArticle

Abstract

Melanoma-associated retinopathy (MAR) is a rare paraneoplastic retinal disorder usually occurring in the context of metastatic melanoma. Patients present with night blindness, photopsias and a constriction of the visual field. MAR is an auto-immune disorder characterized by the production of autoantibodies targeting retinal proteins, especially autoantibodies reacting to the cation channel TRPM1 produced in melanocytes and ON-bipolar cells. TRPM1 has at least three different isoforms which vary in the N-terminal region of the protein. In this study, we report the case of three new MAR patients presenting different anti- TRPM1 autoantibodies reacting to the three isoforms of TRPM1 with variable binding affinity. Two sera recognized all isoforms of TRPM1, while one recognized only the two longest isoforms upon immunolocalization studies on overexpressing cells. Similarly, the former two sera reacted with all TRPM1 isoforms on western blot, but an immunoprecipitation enrichment step was necessary to detect all isoforms with the latter serum. In contrast, all sera labelled ON-bipolar cells on Tprm1+/+ but not on Trpm1-/- mouse retina as shown by coimmunolocalization. This confirms that the MAR sera specifically detect TRPM1. Most likely, the anti-TRPM1 autoantibodies of different patients vary in affinity and concentration. In addition, the binding of autoantibodies to TRPM1 may be conformation-dependent, with epitopes being inaccessible in some constructs (truncated polypeptides versus full-length TRPM1) or applications (western blotting versus immunohistochemistry). Therefore, we propose that a combination of different methods should be used to test for the presence of anti-TRPM1 autoantibodies in the sera of MAR patients.

Original languageEnglish
Article numbere0231750
JournalPloS one
Volume15
Issue number4
DOIs
StatePublished - Apr 2020

Fingerprint Dive into the research topics of 'Identification and characterization of novel TRPM1 autoantibodies from serum of patients with melanoma-associated retinopathy'. Together they form a unique fingerprint.

  • Cite this

    Varin, J., Reynolds, M. M., Bouzidi, N., Tick, S., Wohlschlegel, J., Becquart, O., Michiels, C., Dereure, O., Duvoisin, R. M., Morgans, C. W., Sahe, J. A., Samaran, Q., Guillot, B., Pulido, J. S., Audo, I., & Zeitz, C. (2020). Identification and characterization of novel TRPM1 autoantibodies from serum of patients with melanoma-associated retinopathy. PloS one, 15(4), [e0231750]. https://doi.org/10.1371/journal.pone.0231750